Business Wire

SpeeDx Develops Multiplex Test for Respiratory Viruses

Share

SpeeDx Pty. Ltd. today announced submission of their PlexPCR® RespiVirus test to the Therapeutic Goods Administration (TGA). The company anticipates clearance in time for the Australian 2019 flu season. The test utilises SpeeDx market-leading PlexPCR® multiplex technology, designed for detection of 14 targets representing 10 viral respiratory-illness causing pathogens.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190212006006/en/

SpeeDx PlexPCR RespiVirus offers excellent sensitivity and improved productivity for fast and reprod ...

SpeeDx PlexPCR RespiVirus offers excellent sensitivity and improved productivity for fast and reproducible respiratory virus testing. (Graphic: Business Wire)

“We are excited to expand our infectious disease portfolio into the respiratory market,” said Colin Denver, SpeeDx CEO. “SpeeDx patented technology enables multiple targets to be easily combined into a single test, which means laboratories can get results for more patients over the course of a work day compared to standard technologies. This is particularly important during the peak respiratory-testing seasons when laboratories are resource challenged.”

The SpeeDx PlexPCR RespiVirus test detects major respiratory pathogens including Influenza A, Influenza B, Rhinoviruses (A & B), Respiratory Syncytial Viruses (A & B), Human metapneumovirus, Adenoviruses, and Human parainfluenza viruses 1, 2, 3 and 4. The impact of these respiratory pathogens is seen most heavily during late winter-early spring, with combined health and economic impacts attributed to absenteeism, hospitalisation, and serious complications leading to admission in intensive care, and in some instances death. The most severe health risks are attributed to influenza illness in infants, elderly, and immune-compromised people.1 The 2017 Australian Flu season was particularly severe with over 233,453 reported cases of influenza (2.5 x the number reported in 2016), with almost 30,000 hospital admissions and 745 deaths – higher than any previous year to date.2

The anticipated addition of PlexPCR RespiVirus will add to SpeeDx’s infectious disease test portfolio that includes PlexPCR® VHS, a multiplex lesion diagnostic test for Herpes Viruses (Type-1 & -2); Varicella Zoster Virus, responsible for causing chicken pox and shingles; and Treponema pallidum, the bacterium that causes syphilis. Other tests in the SpeeDx portfolio specialise in sexually transmitted infections (STIs) and genetic mutations for antibiotic resistance. Tests include ResistancePlus® MG – clinically proven to improve cure rates for patients infected with the STI Mycoplasma genitalium (Mgen) by using antibiotic resistance information included in the test result.3 SpeeDx also markets ResistancePlus® GC (CE-IVD)* - the first commercial test to detect Neisseria gonorrhoeae, the bacterium causing gonorrhoea, and genetic markers for ciprofloxacin susceptibility, enabling doctors to treat patients with an inexpensive and simple oral antibiotic.

*not available in the U.S. or A.U.

About Respiratory Viruses

Respiratory tract infections (RTIs) are responsible for the majority of primary health care consults,4 causing high morbidity and mortality, particularly in young, elderly or immune-compromised populations.5 Viral agents cause up to 90% of RTIs - mainly human rhinoviruses (RhV), influenza viruses, and respiratory syncytial virus (RSV).6 Symptoms and duration include: common cold, sinusitis, pharyngitis, epiglottitis, and laryngotracheitis.7

Bacterial infection is difficult to establish without performing diagnostic tests, thus empirical use of antibiotics is discouraged in treatment guidelines.8-12 Most uncomplicated infections will clear within 2-5 days without medical intervention.13,14 However, accurate detection of respiratory viruses is important in patient care, guiding therapy and infection control measures.15 Most importantly, distinguishing bacterial RTIs from viral is essential to avoid unnecessary antibiotic prescription. Pathogen identification is also a key component in management of acute respiratory infection outbreaks and pandemic preparedness strategies.15,16

About PlexPCR®

PlexPCR® kits are highly multiplexed qPCR tests for detection of infectious diseases. Powered by proprietary PlexZyme® and PlexPrime® technologies, the product line offers high multiplexing capability for better, more streamlined infectious disease management, and improved laboratory workflow.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see https://plexpcr.com

References

  1. http://www.who.int/mediacentre/factsheets/fs211/en/
  2. Australian Government. 2017 Influenza Season in Australia. Information Brief (22 November 2017).
  3. Read T R H, et al. CID 68(4): 554-560.
  4. Office of Population Censuses and Surveys. Series MB5,3. London: HMSO,1995
  5. http://www.erswhitebook.org/chapters/the-burden-of-lung-disease/
  6. Brittain-Long et al. Scand J Infect Dis 44(1):9-17
  7. https://www.ncbi.nlm.nih.gov/books/NBK8142/
  8. U.S. Department of Health and Human Services. Research Protocol – May 23, 2014 (Update)
  9. Harris AM et al. Annals of Int. Med. 164(6):425-435.
  10. https://www.nice.org.uk/guidance/CG69
  11. Woodhead et al. CMI 2011;17(6):1–24.
  12. Mahony JB. Clin. Microbiol. Rev. 2008;21(4):716–747
  13. Harris AM et al. Annals of Internal Medicine 164(6):425-435.
  14. https://www.nice.org.uk/guidance/CG69
  15. Ginocchio, CC & McAdam AJ. J Clin Micro. 2011; 49(9): S44–S48
  16. https://www.gov.uk/government/publications/acute-respiratory-infections-investigating-outbreaks-and-clusters-in-schools

Contact information

Madeline O’Donoghue
SpeeDx Global Marketing Manager
madelineo@speedx.com.au
+61 406 582 808

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mori Building Unveils Massive Urban Regeneration Project in Central Tokyo22.8.2019 07:00:00 EESTPress release

Mori Building Co., Ltd., a leading urban landscape developer, has begun construction on its “Toranomon-Azabudai District Category 1 Urban Redevelopment Project,” a massive urban regeneration project aimed at revitalizing a large area of central Tokyo. A groundbreaking ceremony was held on August 5 and project completion is scheduled for the end of March 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005445/en/ Image of Office Lobby (Graphic: Business Wire) The core concept of the Toranomon-Azabudai Project is that of a “Modern Urban Village,” a unique neighborhood that will combine the sophistication of a megalopolis with the intimacy of a small village in the heart of Tokyo. It will cover an area of approximately 8.1 hectares, similar to that of New York’s Rockefeller Center, and will feature extensive greenery totaling 24,000 m2 including a 6,000 m2 central square. Total floor area will be 860,400 m2, including

Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency22.8.2019 02:01:00 EESTPress release

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), Mundipharma welcomes the news that the European Medicines Agency (EMA) has accepted the licence extension submission for these two medicines to treat stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria as an adjunct to standard of care in adults with type 2 diabetes mellitus (T2DM). The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient population when used in addition to standard of care. “Chronic kidney disease is a serious complication of type 2 diabetes, which can increase patients’ risk of developing end-stage renal disease and may reduce their life expectancy by several years.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma. “If approved, this licence

Triton Digital Releases Webcast Metrics Rankings for the Top Digital Audio Properties for April 201921.8.2019 23:00:00 EESTPress release

Triton Digital®, the global technology and services leader to the digital audio and podcast industry, released today its monthly Webcast Metrics® rankers for April 2019. The global rankers, in addition to the U.S., LATAM, and EMEA regional rankers provide insight into the top-performing streaming audio stations and networks around the world for the month of April. The full results of the Global & Regional Rankers for April 2019 can be found here: https://www.tritondigital.com/resources/monthly-rankers/rankers-archive The Webcast Metrics streaming measurement service is the industry standard for online audio consumption data. It provides credible, validated data that enables audio publishers around the world to analyze the consumption of their audio content by daypart, device type, geography, distribution platform, and more. About Triton Digital Triton Digital® is the global technology and services leader to the digital audio and podcast industry. Operating in more than 40 countries, Tr

Celsius Partners With Tether to Bring USDT its Highest Interest-earning Wallet at 10.53% APR21.8.2019 18:15:00 EESTPress release

Celsius Network (https://celsius.network/), the industry-leading cryptocurrency platform, announces today its partnership with Tether, a stablecoin which pegs its value to the US dollar. The Celsius app now supports the USDT ERC20 stablecoin allowing USDT holders to earn rewards and request loans on a far less volatile asset than other cryptocurrencies. Celsius users can now request a loan issued in USDT, in addition to the existing stablecoins and fiat loan options available through Celsius, at rates as low as 4.95% APR. The company currently offers interest income of 8.1% APR on USDT deposits and 10.53% when paid in CEL tokens. At the same time, using stablecoins reduces capital costs, allowing Celsius to offer loans at a lower rate. Celsius has achieved notable milestones in the past year to drive the decentralization of traditional financial structures: Over $2.2 billion worth of coin loans originated since July 2018 Over $350 million AUM in customer deposits and collateral from lo

The World's First 5nm Generation AI Chip is Taped Out - TeraPixel Technologies, Inc.21.8.2019 17:00:00 EESTPress release

TeraPixel Technologies Inc. (Representative: Naoki Kawahara) taped out “Extrixa Processor” as the first deep-learning AI product on March 8, 2019 as the world's first chip that uses TSMC 5nm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005023/en/ Picture of Mechanical Sample for 5nm Deep Learning AI Processor (Photo: Business Wire) Wafer equipped with ASIC implemented in the world's most advanced process rolls out on August 25 and is scheduled to be available in early September after assembly testing. This 5nm process will be used to check the core performance and power consumption since SRAM cells were not yet prepared at the time of tape-out in March. In the first quarter of 2020, we will tape out the second version with the same functions as the product version with SRAM and other functional blocks. TeraPixel has R & D technology for massively parallel processors with many cores, aiming for the world's highest le

Cummins President and COO Rich Freeland Retiring21.8.2019 16:00:00 EESTPress release

Cummins Inc. (NYSE: CMI) announced today that President and COO, Rich Freeland will retire after forty years of service with Cummins. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005396/en/ Rich Freeland (Photo: Business Wire) As part of Cummins’ successions plans, the following leadership appointments are also taking place, all of which are effective October 15. Distribution President Tony Satterthwaite will succeed Freeland as President and COO. Components President Tracy Embree will succeed Satterthwaite as Distribution Business President. Chief Technical Officer Jennifer Rumsey will succeed Embree as Components Business President. Jim Fier will succeed Rumsey as Chief Technical Officer. “I want to personally thank Rich for his many contributions to Cummins and his friendship and support over the 25 years I have known and worked with him,” said Tom Linebarger, Chairman and CEO, Cummins Inc. “He is one of the most

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom